Silexion Therapeutics Corp — Form SCHEDULE 13D/A
Filed August 19, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
This is an amended Schedule 13D filing by Moringa Sponsor, LP (via Moringa Acquisition Corp, 250 Park Avenue, New York) regarding beneficial ownership in Silexion Therapeutics Corp (Israeli biotech, ~$4.6M assets). The filing itself contains no substantive detail on ownership percentage, share count, transaction amount, or date of change—only administrative metadata indicating the amendment was filed 2026-08-19. The specific amended facts are not disclosed in this header document.
Why this rating
Amendment to existing disclosure; no quantitative changes or transaction details visible. Routine 13D update for micro-cap target.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.